HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Interpretation of The "14th Five-Year Plan" For the Development of China Pharmaceutical Industry

Would the Cheap Versions of Oral COVID-19 Antiviral Bring New Opportunities for Chinese Companies?

China Healthcare Weekly (Feb.11)- “14th Five-Year Plan” For Medical Beauty, Wuxi Biologics, Innovent

Tinavi Medical Technologies (688277.CH) - Time Is Running Out for Tinavi

Anke Biotechnology (300009CH) Vs Changchun High & New Tech (000661CH)-Growth Hormone VBP and Outlook

Pre-IPO MicroPort MedBot - The Core Products, the Business Model and the Concerns

Gravity Works As WeWork Doesn't; Now Plan B

Equity Bottom-Up

Shanghai MicroPort MedBot Group / Equity Bottom-Up

Shanghai MicroPort MedBot Group (2252 HK)

<ul>
<li>Recently, MicroPort MedBot’s Toumai laparoscopic surgical robot has obtained a registration certificate for launching by NMPA, indicating the hope of breaking the monopoly of Da Vinci robots in the market.</li>
<li>The strong policy support as well as the medical insurance coverage offer a viable way for the commercialization of surgical robots in China, which is very important. </li>
<li>Although it would take some time to improve the overall market penetration in China, we are still optimistic about the outlook of <a href="https://www.smartkarma.com/entities/shanghai-microport-medbot-group-co-ltd" target="_blank" data-smartkarma-citation="entities:33485:1" rel="noopener">Shanghai MicroPort MedBot Group (2252 HK)</a>.</li>
</ul>


Recently, MicroPort MedBot’s Toumai laparoscopic surgical robot has obtained a registration certificate for launching by NMPA, indicating the hope of breaking the monopoly of Da Vinci robots in the market.
The strong policy support as well as the medical insurance coverage offer a viable way for the commercialization of surgical robots in China, which is very important. 
Although it would take some time to improve the overall market penetration in China, we are still optimistic about the outlook of Shanghai MicroPort MedBot Group (2252 HK).


Shanghai MicroPort MedBot Group (2252.HK) - Optimistic About the Outlook